Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release May 09 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 5 pages · English

Summary by 6ix AI

This trial aims to assess the efficacy and safety of Saroglitazar Mg in patients who are not adequately controlled on standard first-line treatments. The announcement highlights the importance of new treatment options for patients suffering from this rare liver disease.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 09, 2024, titled "Zydus Announces Completion of Enrolment for EPICS IIITM Phase 2b/3 trial evaluating Saroglitazar Mg in treatment of Primary Biliary Cholangitis".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases